Epidemiology, prevention, and early detection of breast cancer

Current Opinion in Oncology

Volumn 10, Issue 6, 1998, Pages 492-497

  Alberg, Anthony J ^a   Visvanathan, Kala ^a   Helzlsouer, Kathy J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIESTROGEN; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; ESTROGEN RECEPTOR; ORAL CONTRACEPTIVE AGENT; ORGANOCHLORINE DERIVATIVE; RALOXIFENE; TAMOXIFEN;

ALCOHOL CONSUMPTION; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; DIET; DNA POLYMORPHISM; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; ENVIRONMENTAL EXPOSURE; ESTROGEN THERAPY; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

EID: 0031727217     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199811000-00003     Document Type: Review

References (60)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics, 1998. CA Cancer J Clin 1998, 48:6-29.
2. Murphy MFG, Broeders MJM, Carpenter LM, Gunnarskog J, Leon DA: Breast cancer risk in mothers of twins. Br J Cancer 1997, 75:1066-1068.
3. Bonnier P, Romain S, Dilhuydy JM, Bonichon F, Julien FP, Charpin C, et al.: Influence of pregnancy on the outcome of breast cancer: a case-control study. Int J Cancer 1997, 72:720-727.
4. Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M: Time since childbirth and prognosis in primary breast cancer: population based study. Br Med J 1997, 315:851-855.
5. Kroman N, Jensen M-B, Melbye M, Wohlfahrt J, Mouridsen HT: Should women be advised against pregnancy after breast cancer treatment? Lancet 1997, 350:319-322.
6. Enger SM, Ross RK, Henderson BE, Bernstein L: Breastfeeding history, pregnancy experience and risk of breast cancer. Br J Cancer 1997, 76:118-123.
7. Freudenheim JL, Marshall JR, Vena JE, Moysich KB, Muti P, Laughlin R, et al.: Lactation history and breast cancer risk. Am J Epidemiol 1997, 146:932-938.
8. Enger SM, Ross RK, Paganini-Hill A, Bernstein L: Breastfeeding experience and breast cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 1998, 7:365-369.
9. Ingram D, Sanders K, Kolybaba M, Lopez D: Case-control study of phytoestrogens and breast cancer. Lancet 1997, 350:990-994.
10. Schatzkin A, Longnecker MP: Alcohol and breast cancer: where are we now and where do we go from here? Cancer 1994, 74:1101-1110.
11. Smith-Warner SA, Spiegelman D, Yaun S-S, vandenBrandt PA, Folsom AR, Goldbohm RA, et al.: Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998, 279:535-540. The results of a pooled analysis of data from six cohort studies showed that women who drank more than two drinks per day had an elevated risk of breast cancer compared with non-drinkers.
12. Bowlin SJ, Leske MC, Varma A, Nasca P, Weinstein A, Caplan L: Breast cancer risk and alcohol consumption: results from a large case-control study. Int J Epidemiol 1997, 26:915-923.
13. Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, Doll R: Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 1997, 337:1705-1714.
14. Singletary K: Ethanol and experimental breast cancer: a review. Alcohol Clin Exp Res 1997, 21:334-339.
15. Muti P, Trevisan M, Micheli A, Krogh V, Bolelli G, Sciajno R, et al.: Alcohol consumption and total estradiol in premenopausal women. Cancer Epidemiol Biomarkers Prev 1998, 7:189-193.
16. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350:1047-1059. Most of the worldwide data concerning the association between hormone replacement therapy and breast cancer was pooled, enabling careful consideration of the timing and duration of the exposure in relation to disease onset. The results indicated that current users were at increased risk of breast cancer, and that the risk increased with duration of use. After stopping use, the risk of breast cancer decreased back to baseline levels after 5 years.
17. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al.: Postmenopausal hormone therapy and mortality. N Engl J Med 1997, 336:1769-1775. Using data from a longitudinal follow-up of nurses, this study was designed to evaluate the association between hormone replacement therapy and mortality while accounting for the fact that women who take hormone replacement therapy may be healthier than women who do not. Overall mortality was lower among hormone users than non-users, but the benefit was attenuated among long-term users due to an increased risk of breast cancer.
18. Hunter DJ, Hankinson SE, Laden F, Colditz GA, Manson JE, Willett WC, et al.: Plasma organochlorine levels and the risk of breast cancer. N Engl J Med 1997, 337:1253-1258.
19. Moysich KB, Ambrosone CB, Vena JE, Shields PG, Mendola P, Kostyniak P, et al.: Environmental organochlorine exposure and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998, 7:181-188.
20. Lopez-Carrillo L, Blair A, Lopez-Cervantes M, Cebrian M, Rueda C, Reyes R, et al.: Dichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case-control study from Mexico. Cancer Res 1997, 57:3728-3732.
21. Schecter A, Toniolo P, Dai LC, Thuy LTB, Wolff MS: Blood levels of DDT and breast cancer risk among women living in the north of Vietnam. Arch Environ Contam Toxicol 1997, 33:453-456.
22. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY: A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the Island of Guernsey. Br J Cancer 1997, 75:1075-1079.
23. Kabat GC, Chang CJ, Sparano JA, Sepkovic DW, Hu X-P, Khalil A, et al.: Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997, 6:505-509.
24. Zheng W, Dunning L, Jin F, Holtzman J: Urinary estrogen metabolites and breast cancer: a case-control study [letter]. Cancer Epidemiol Biomarkers Prev 1998, 7:85-86.
25. Khan SA, Rogers MAM, Khurana KK, Meguid MM, Numann PJ: Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1997, 89:37-42.
26. Pharoah PDP, Day NE, Duffy S, Easton DF, Ponder BAJ: Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997, 71:800-809. A detailed consideration of the epidemiologic evidence concerning the risk of breast cancer among women with a family history of breast cancer.
27. McCredie M, Paul C, Skegg DCG, Williams S: Family history and risk of breast cancer in New Zealand. Int J Cancer 1997, 73:503-507.
28. Negri E, Braga C, LaVecchia C, Franceschi S, Parazzini F: Family history of cancer and risk of breast cancer. Int J Cancer 1997, 72:735-738.
29. Muhonen T, Eerola H, Vehmanen P, Nevanlinna H, Aktan K, Blomqvist C, et al.: Breast cancer risk estimation in families with history of breast cancer. Br J Cancer 1997, 76:1228-1231.
30. Egan KM, Stampfer MJ, Rosner BA, Trichopoulos D, Newcomb PA, Trentham-Dietz A, et al.: Risk factors for breast cancer in women with a breast cancer family history. Cancer Epidemiol Biomarkers Prev 1998, 7:359-364.
31. Yang Q, Khoury MJ, Rodriguez C, Calle EE, Tatham LM, Flanders WD: Family history score as a predictor of breast cancer mortality: prospective data from the Cancer Prevention Study II, United States, 1982-1991. Am J Epidemiol 1998, 147:652-659.
32. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, et al.: BRCA1 sequence analysis in women at high risk for susceptibility mutations. JAMA 1997, 278:1242-1250.
33. Verhoog LC, Brekelmans CTM, Seynaeve C, vandenBosch LMC, Dahmen G, vanGeel AN, et al.: Survival and tumor characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 1998, 351:316-321.
34. Johannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998, 16:397-404.
35. Audrain J, Rimer B, Cella D, Garber J, Peshkin BN, Ellis J, et al.: Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? J Clin Oncol 1998, 16:133-138.
36. Groopman J: Decoding destiny. New Yorker. February 9, 1998; 42-47.
37. Waldholz M: A cancer survivor's genetic time bomb. Wall Street Journal. November 10, 1997; B1-B13.
38. Trafford A: The gift of choice. Washington Post. March 10, 1998; Health section:6.
39. Schrag D, Kuntz KM, Garber JE, Weeks JC: Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997, 336:1465-1471.
40. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI: Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA-2 positive patients. J Clin Oncol 1998, 16:979-985.
41. Lavigne JA, Helzlsouer KJ, Huang H-Y, Strickland PT, Bell DA, Selmin O, et al.: An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997, 57:5493-5497.
42. Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, et al.: Genetic polymorphisms in catechol-O-methyl transferase, menopausal status, and breast cancer risk. Cancer Res 1998, 58:2107-2110.
43. Helzlsouer KJ, Selmin O, Huang H-Y, Strickland PT, Hoffman S, Alberg AJ, et al.: Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 1998, 90:512-518.
44. Kelsey KT, Hankinson SE, Colditz GA, Springer K, Garcia-Closas M, Spiegelman D, et al.: Glutathione S-transferase class u deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol Biomarkers Prev 1997, 6:511-515.
45. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF: Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998, 58:65-70.
46. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE: A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997, 57:1063-1065.
47. Ishibe N, Hankinson SE, Colditz GA, Spiegelman D, Willett WC, Speizer FE, et al.: Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res 1998, 58:667-671.
48. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al: Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996, 276:1494-1501.
49. Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, et al.: A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis 1997, 18:2127-2132.
50. Millikan RC, Pittman GS, Newman B, Tse CKJ, Selmin O, Rockhill B, et al: Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998, 7:371-378.
51. Greenwald P, Kelloff G, Burch-Whitman C, Kramer BS: Chemoprevention. CA Cancer J Clin 1995, 45:31-49.
52. Smigel K: Breast cancer prevention trial shows major benefit, some risk. J Natl Cancer Inst 1998, 90:647-648.
53. Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, et al.: Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial [abstract]. Proc Am Soc Clin Oncol 1998, 17:2a.
54. Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A, et al.: Incident primary breast cancers are reduced by raloxifene: integrated data from multicienter, double-blind, randomized trials in approximately 12,000 postmenopausal women [abstract]. Proc Am Soc Clin Oncol 1998, 17:122a.
55. Nelson NJ: Anti-estrogens come of age: a pioneer looks back. J Natl Cancer Inst 1998, 90:646-647.
56. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:1641-1647.
57. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW: Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998, 338:1089-1096.
58. Pisano ED, Earp JA, Gallant TL: Screening mammography behavior after a false positive mammogram. Cancer Detect Prev 1998, 22:161-167.
59. Duijm LEM, Guit GL, Zaat JOM, Koomen AR, Willebrand D: Sensitivity, specificity and predictive values of breast imaging in the detection of breast cancer. Br J Cancer 1997, 76:377-381.
60. Baines CJ, Vidmar M, McKeown-Eyssen G, Tibshirani R: Impact of menstrual phase on false-negative mammograms in the Canadian National Breast Screening Study. Cancer 1997, 80:720-724.